Atreca Posts Narrower Q2 Loss
4:51AM ET 8/14/2019 MT NewswiresDrug maker Atreca (BCEL) reported late Tuesday a Q2 net loss of $3.67 per diluted share, narrower than the loss reported a year earlier of $4.13. Two...
Quotes Snapshot > BCEL
Atreca Inc BCEL:NASDAQ
Last Price$21.31Cboe Real-Time Last Sale as of 3:38PM ET 8/22/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.34(6.71%)
Bid (Size)$19.86 (100)
Ask (Size)$21.44 (200)
Day Low / High$19.33 - 23.38
Volume114.6 K
Read more news Recent News
Analyst Actions: Cowen Starts Atreca at Outperform
10:02AM ET 7/15/2019 MT NewswiresAtreca's (BCEL) average rating among analysts is a buy, with an average price target of $26. Price: 17.52, Change: +0.89, Percent Change: +5.37 ...
Analyst Actions: Evercore ISI Starts Atreca at Outperform, $35 PT
10:01AM ET 7/15/2019 MT NewswiresAtreca's (BCEL) average rating among analysts is a buy, with an average price target of $26. Price: 17.52, Change: +0.89, Percent Change: +5.37 ...
Analyst Actions: Canaccord Genuity Starts Atreca at Buy, With $23 Price Target
10:00AM ET 7/15/2019 MT NewswiresAtreca's (BCEL) average rating among analysts is a buy, with an average price target of $26. Price: 17.52, Change: +0.89, Percent Change: +5.37 ...
View all Commentary and Analysis
Prime Day And FAANGs Out In DC (Stocks To Watch Podcast)
7:35AM ET 7/14/2019 Seeking AlphaStocks To Watch: Prime Day And FAANGs Out In DC
8:51AM ET 7/13/2019 Seeking AlphaMedicare Part D Proposed Restructuring Would Be Impactful To Pharmaceutical Companies
7:51AM ET 7/12/2019 Seeking AlphaU.S. IPO Weekly Recap: WORK's Direct Listing Works As Slack And 6 Others Go Public
9:46AM ET 6/22/2019 Seeking AlphaCompany Profile
Business DescriptionAtreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA. View company web site for more details
| Address | 500 Saginaw Drive Redwood, California 94063-4750 |
| Phone | +1.650.595.2595 |
| Number of Employees | 85 |
| President, Chief Executive Officer & Director | John A. Orwin |
| Chief Financial Officer | Herbert C. Cross |
| Chief Technology Officer | Guy Cavet |
| Senior Vice President-Research | Daniel Emerling |
Company Highlights
| Price Open | $19.89 |
| Previous Close | $19.97 |
| 52 Week Range | $10.29 - 23.38 |
| Market Capitalization | $469.1 M |
| Shares Outstanding | 22.0 M |
| Sector | Commercial Services |
| Industry | Miscellaneous Commercial Services | Next Earnings Announcement | 11/12/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$4.42 |
| Beta vs. S&P 500 | N/A |
| Revenue | $961.0 K |
| Net Profit Margin | -2,798.86% |
| Return on Equity | -138.50% |
Analyst Ratings as of 07/12/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |